Bennicas & Associates, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Bennicas & Associates, Inc.
- $157 Million
- Q4 2022
A detailed history of Bennicas & Associates, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bennicas & Associates, Inc. holds 1,260 shares of REGN stock, worth $614,703. This represents 0.58% of its overall portfolio holdings.
Number of Shares
1,260
Previous 1,260
-0.0%
Holding current value
$614,703
Previous $909,000
-0.0%
% of portfolio
0.58%
Previous 0.53%
Shares
8 transactions
Others Institutions Holding REGN
# of Institutions
1,471Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$4.59 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.12 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$2.76 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.34 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$1.95 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $52.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...